Drugs / AMG 820
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01444404 | Mar 2008 → Feb 2014 | cancer | AmMax Bio, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02713529 | Apr 2016 → Jan 2019 | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | AmMax Bio, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 820 | “A Phase1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors” NCT02713529 ↗ |
| Action | Inhibit | “c-fms antagonistic antibody” NCT01444404 ↗ |
| Modality | Monoclonal antibody | “fully human IgG2 c-fms antagonistic antibody” NCT01444404 ↗ |
| Target | CSF1R | “c-fms antagonistic antibody” NCT01444404 ↗ |